Dynamic Changes in Human Microbiome Predict the Risk of Adverse Outcomes in Patients With Acute Ischemic Stroke: a Multicenter Prospective Cohort Study

NCT ID: NCT06240468

Last Updated: 2024-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-10

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

(1) The main purpose

To explore the predictive value of human microbiome and its metabolome for adverse prognosis in patients with acute ischemic stroke (AIS).

(2) Secondary purposes

1. To explore the characteristics of cross-regional disturbance of human microbiome in stroke patients;
2. To investigate the characteristics and rules of bacterial flora changes before and after recurrent apoplexy;
3. Markers closely related to AIS prognosis and cognitive emotional complications were excavated by metagenomic, metabolic, peptide and imaging groups.
4. To explore the relationship between serum markers of ultra early stage and prognosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, prospective clinical cohort study. In this study, 2000 patients with AIS were continuously enrolled in a multicenter study, and neurological function scores (including NIHSS, mRS And ADL scores) were evaluated during and after hospitalization (3 months, 6 months, 12 months) by outpatient/telephone follow-up, and recurrent stroke and other cardiovascular and cerebrovascular events were recorded. Besides, periodontal swabs, urine, feces and blood samples were collected at multiple time points (Residual blood after the first clinical examination was collected for patients with very early stage, and blood, urine, feces and periodontal swabs were collected the next day after admission, before discharge, 3 months and 6 months after admission. Since the collection time of fecal specimens is difficult to control, only two specimens should be collected 48 hours apart during hospitalization. The first specimen should be collected as early as possible, and the time of specimen separation should be recorded.

Baseline data collection and discharge neurological function score were completed for the enrolled AIS patients before discharge, and the final diagnosis, stroke etiology classification, lifestyle survey (1 year ago), and relevant examination and treatment during hospitalization were recorded. Neurological function score, lifestyle survey, new cardiovascular and cerebrovascular events and biological specimen collection (blood, urine, feces, periodontal swab) were recorded during outpatient visits 3 months and 6 months after admission. Telephone follow-up was conducted 12 months after admission, mRS Score, ADL score and new cardiovascular and cerebrovascular events were recorded.

For the patients (750 cases) who met the criteria for inclusion in the cognitive emotion subcohort, outpatient emotional and cognitive psychological assessment was also required before discharge, 3 months and 6 months after admission on the basis of the AIS cohort.

For the subcohort with recurrence within 1 year, only data collection during hospitalization (baseline hospitalization data) and biological specimen collection during hospitalization (residual blood after the first laboratory examination was retained for patients in the very early stage, and blood, urine, feces, and periodontal swabs were collected the next day after admission and before discharge. As the time of fecal sample collection is difficult to control, it only needs to be 48 hours between hospitalization), and no follow-up will be conducted after discharge.

In addition, 500 patients without stroke were recruited as healthy control group according to the prescribed inclusion criteria.

No randomization or any study protocol-driven treatment will be administered or provided to the subject during the study. If clinically applicable, treatment decisions and treatment options are made at the discretion of the treating physician.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AIS patient

AIS inclusion criteria

(1) Inclusion criteria

1. Meet the diagnostic criteria for AIS or TIA;
2. Age 18-80 years old;
3. within 7 days of the onset of stroke;
4. Sign informed consent, provide relevant medical history and biological specimens;
5. Have lived in the local city for the last three years.

(2) Exclusion criteria

1. Patients with recurrent stroke within the past year when first enrolled;
2. mRS \> 2 points before stroke onset;
3. malignant tumor;
4. Liver and kidney dysfunction (alanine aminotransferase or aspartate aminotransferase \>2 times the upper limit of normal, creatinine \> 1.5 times the upper limit of normal);
5. History of drug abuse and chemical poisoning (e.g. pesticide poisoning);
6. In the acute stage of stroke (within 7 days from the onset of stroke) stool specimens could not be collected.

not have

Intervention Type OTHER

not have

Cognitive/emotional subcohort

(I) Inclusion criteria:

1. It has been included in the AIS queue, meeting the inclusion criteria of the main AIS queue;
2. NIHSS≤15; (II) Exclusion criteria:

(1) Patients with aphasia and unable to cooperate in completing the cognitive/emotional assessment during the study; (2) previous severe mental disorder and dementia (AD8 scale score ≥2); (3) A history of severe anxiety and depression; (4) Previous history of seizures.

not have

Intervention Type OTHER

not have

healthy person

health

not have

Intervention Type OTHER

not have

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

not have

not have

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet the diagnostic criteria for AIS or TIA
* Age 18-80 years old
* Within 7 days of the onset of stroke
* Sign informed consent, provide relevant medical history and biological specimens
* Have lived in the local city for the last three years

Exclusion Criteria

* Patients with recurrent stroke within the past year when first enrolled
* mRS \> 2 points before stroke onset
* malignant tumor
* Liver and kidney dysfunction (alanine aminotransferase or aspartate aminotransferase \>2 times the upper limit of normal, creatinine \> 1.5 times the upper limit of normal)
* History of drug abuse and chemical poisoning (e.g. pesticide poisoning)
* In the acute stage of stroke (within 7 days from the onset of stroke) stool specimens could not be collected
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zhujiang Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mengxi Li

Role: CONTACT

15013048680

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hongwei Zhou, Professor

Role: primary

18688489622

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CALM2003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.